Product image of Manitol Labesfal (Mannitol) supplied by GNH India

Manitol Labesfal

Active Ingredient:
Mannitol
Origin:
EU

Manitol Labesfal (Mannitol)

Mannitol, the active ingredient in Manitol Labesfal, is an osmotic diuretic presented as an injection solution for intravenous use. It is employed to lower elevated intracranial and intraocular pressures, to promote diuresis in acute kidney injury, and to protect renal function during procedures that involve nephrotoxic agents.

GNH India supplies Manitol Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide. The company ensures product quality through strict regulatory compliance and cold‑chain logistics where required.

Manufacturer / TM Owner

Labesfal Laboratorios Almiro, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Manitol Labesfal, an osmotic diuretic, is used in clinical situations where rapid fluid shifts are needed to lower pressure or enhance renal clearance.

  • Elevated intracranial pressure: helps lower pressure to prevent brain herniation.
  • Elevated intraocular pressure: reduces pressure to protect optic nerve function.
  • Nephrotoxic procedures: provides renal protection by promoting diuresis.
  • Acute kidney injury: facilitates fluid removal and improves urine output.

How It Works

  • Mannitol acts as an osmotically active agent that raises plasma osmolarity when administered intravenously. The increased osmotic gradient draws water from intracellular and interstitial compartments into the vascular space, expanding plasma volume and promoting renal filtration. This osmotic diuresis enhances urinary output and reduces tissue edema, thereby lowering intracranial and intraocular pressures and protecting renal function during exposure to nephrotoxic agents.

Side Effects

Mannitol may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate discomfort.
  • Nausea or vomiting: gastrointestinal upset.
  • Thirst or dry mouth: due to osmotic effect.
  • Transient hypotension: drop in blood pressure after infusion.
  • Electrolyte imbalance: especially sodium and potassium shifts.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Acute renal failure: worsening kidney function.
  • Pulmonary edema: fluid accumulation in lungs.
  • Severe hyponatremia: dangerously low serum sodium.
  • Anaphylactic reaction: rare allergic response.
  • Hemolysis: destruction of red blood cells.
  • Severe hypotension: marked drop in blood pressure requiring intervention.

Precautions & Warnings

Prior to using Manitol Labesfal, clinicians should consider several safety measures.

  • Renal function: assess baseline creatinine and urine output.
  • Electrolytes: monitor serum sodium and potassium levels.
  • Cardiovascular status: watch for signs of volume overload or hypotension.
  • Neurological status: observe intracranial pressure trends.
  • Pregnancy: use only if potential benefits justify potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mannitol can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Loop diuretics: additive diuretic effect may cause dehydration.
  • Insulin: may mask hypoglycemia symptoms.
  • ACE inhibitors: increased risk of renal impairment.

Moderate Interactions (Monitor Closely)

  • Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function closely.
  • Antihypertensives: may enhance hypotensive effect.
  • Lithium: may raise serum lithium concentrations.

Frequently Asked Questions

Manitol Labesfal is an intravenous osmotic diuretic used to lower elevated intracranial and intraocular pressures, to promote diuresis in acute kidney injury, and to protect renal function during procedures that involve nephrotoxic agents.

Mannitol increases plasma osmolarity after intravenous administration, drawing water from cells and interstitial spaces into the bloodstream. This expands plasma volume, enhances renal filtration, and reduces tissue edema, which helps lower pressure in the brain and eye and supports kidney protection.

The specific dose of Manitol Labesfal is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Dosing regimens are individualized and should follow the prescriber’s instructions.

The safety of Mannitol in pregnancy and lactation has not been fully established. It should be used only when the potential benefits outweigh any possible risks to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Manitol Labesfal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Mannitol is the most widely used osmotic diuretic due to its rapid onset, predictable renal clearance, and effectiveness in reducing intracranial and intraocular pressures. Compared with alternatives such as hypertonic saline, Mannitol offers a more controlled osmotic effect and is preferred in neurosurgical and renal‑protective settings.

Manitol Labesfal should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and potency.

Manitol Labesfal is administered intravenously by a healthcare professional. The solution is typically infused over a specified period, often diluted in compatible IV fluids, with infusion rate adjusted according to the clinical indication and patient response.

Serious risks include acute renal failure, severe hyponatremia, pulmonary edema, and anaphylactic reactions. Patients should be closely monitored for changes in renal function, electrolyte balance, respiratory status, and any signs of allergic response during and after infusion.

Manitol Labesfal is contraindicated in patients with known hypersensitivity to Mannitol, severe renal impairment, active pulmonary edema, or uncontrolled electrolyte disturbances. Caution is also advised for individuals with severe heart failure or those at risk of fluid overload.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.